UBS Group’s Amicus Therapeutics FOLD Stock Holding History

UBS Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-39,300	Closed	-$614K	–	8070
2018 Q2	$614K	Buy	+39,300	New	+$594K	﹤0.01%	4167
2017 Q4	–	Sell	-5,000	Closed	-$75K	–	7928
2017 Q3	$75K	Sell	5,000 -20,000	-80%	-$265K	﹤0.01%	5518
2017 Q2	$252K	Buy	+25,000	New	+$201K	﹤0.01%	4601

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS Group's FOLD Position: Q2 2026 in Review

UBS Group sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 15,957,913 shares — an estimated $231M sold.

UBS Group first reported a position in FOLD in Q4 2014 and held it in 46 quarters. The position peaked at $231M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

UBS Group reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
UBS Group sold 15,957,913 Amicus Therapeutics shares in Q2 2026, an estimated $231M.
UBS Group first reported a position in Amicus Therapeutics in Q4 2014 and held it in 46 quarters.
UBS Group's Amicus Therapeutics position peaked at $231M in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.